Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 versus CLINIMIX 8 14 SULFITE FREE IN DEXTROSE 14 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 versus CLINIMIX 8 14 SULFITE FREE IN DEXTROSE 14 IN PLASTIC CONTAINER.
AMINOSYN 3.5% vs CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
Provides essential amino acids and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism.
Intravenous administration of 500 mL to 1000 mL per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 mL/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Intravenous infusion. Dose individualized based on metabolic requirements, energy expenditure, and clinical status. Typical adult dose: 500 mL to 1000 mL per day, providing 8% amino acids and 14% dextrose, infused at a rate not exceeding 0.1 g/kg/hr of amino acids and 0.5 g/kg/hr of dextrose.
None Documented
None Documented
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Not applicable as individual components (amino acids, dextrose, electrolytes) are not eliminated via first-order kinetics; amino acids have a plasma half-life of minutes to hours depending on metabolic demand and renal function.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
Renal excretion of urea and other nitrogenous waste products; no biliary or fecal elimination of nutrients.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution